Document is current

Article History

Accepted: 21 November 2021

First Online: 10 January 2022

Declarations

:

: No sources of funding were used to assist with the preparation of this review.

: Krista L. Lanctôt has received grants from the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation, the Canadian Institutes of Health Research, the National Institutes of Aging, and the Weston Brain Institute; consulting fees from BioXcel, Cerevel, Eisai, GW Pharma, ICG Pharma, Kondor Pharma, Novo Nordisk, Otsuka, and Praxis; and stock options from Highmark Interactive outside the submitted work. Nathan Herrmann, Laiba Azhar, Raphael W. Kusumo, and Giovanni Marotta have no conflicts of interest that are directly relevant to the content of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: The idea for the review was suggested by Nathan Herrmann. Drafts of the manuscript and literature searches were written and performed by Laiba Azhar, Nathan Herrmann, Krista L. Lanctôt, and Raphael W. Kusumo. All authors reviewed and commented on all versions of the manuscript, approved the final manuscript, and agree to be accountable for the manuscript.